2 registrations that name boswellia as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
All 2 registrations
RecruitingNCT07109843
Effect of Boswellia Serrata on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers
No phase
Medical University of Graz
About 12 people
Started Sep 1, 2025
In plain words A study of boswellia in people 18 and older, run by Medical University of Graz. It plans to enroll about 12 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Chronic Pain; Central Sensitisation; Peripheral Sensitization; Neuroinflammatory Response.
Age: ≥18 years
The exclusion criteria are on the listing.
What it tests, as registered
Boswellia serrata extract; Placebo
Registered summary
This planned study is based on a randomized, placebo-controlled cross-over design. Boswellic acids, the triterpenes found in the gum resins of Boswellia serrata (family: Burseraceae), are traditionally used in the Indian Ayurvedic medicine system as antioxidants and anti-inflammatory agents for treating conditions such as rheumatoid arthritis, chronic bronchitis, asthma, and chronic inflammatory bowel diseases (ulcerative colitis and Crohn's disease). The β-configured pentacyclic triterpenic acids in B. The full summary is on the listing.
Where, as registered
No US site; Austria (1).
Not yet recruitingNCT07867158
Study of Boswellia for Urinary Toxicity in Prostate Cancer Radiotherapy
Phase 2
Brigham and Women's Hospital
About 20 people
Starts Oct 2026 (estimated)
In plain words A Phase 2 study of boswellia in male participants 18 and older, run by Brigham and Women's Hospital. It plans to enroll about 20 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Prostate Cancer.
Patients with pathologically-proven prostate cancer undergoing fractionated radiation for prostate cancer.
Patients must be developing worsening urinary symptoms from radiation as evaluated by treating physician.
Fractionated radiation must be targeted at either the intact prostate or the prostate fossa (surgical bed) in cases of prior prostatectomy.
Radiation fields may also include treatment of the pelvic lymph node basins and/or more distant targets including but not limited to nearby bone metastases and retroperitoneal lymph nodes.
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Boswellia serrata extract
Registered summary
The goal of this clinical trial is to determine whether Boswellia serrata extract is effective at reducing urinary symptoms in patients undergoing radiation for prostate cancer. The main question it aims to answer is whether patients taking Boswellia report significantly improved urinary symptoms at the 1-week timepoint after taking a minimum of two (2) days of Boswellia treatment. Participants will follow a treatment plan of 1500 mg of oral Boswellia, taken three times per day, and will report their symptoms and side effects using a specialized questionnaire.